Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death

Molecular Pharmacology

Volumn 62, Issue 2, 2002, Pages 351-358

  Mullally, J E ^a   Fitzpatrick, F A ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIPHENYL 4H THIOPYRAN 4 ONE; ACHILLIN; ANTINEOPLASTIC AGENT; BENZYLIDENEACETONE; CURCUMIN; DELTA12 PROSTAGLANDIN J2; DIBENZYLIDENEACETONE; DITERPENE; ENZYME INHIBITOR; NSC 156236; NSC 302979; PEPTIDASE; PROSTAGLANDIN B1; PROTEASOME INHIBITOR; PROTEIN P53; SESQUITERPENE DERIVATIVE; SHIKOCCIN; UBIQUITIN ISOPEPTIDASE; UBIQUITIN ISOPEPTIDASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CONTROLLED STUDY; DATA BASE; ENZYME INHIBITION; HUMAN; HUMAN CELL; PHARMACOPHORE; PRIORITY JOURNAL;

CELL DEATH; DATABASES, FACTUAL; ENDOPEPTIDASES; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036070772     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.2.351     Document Type: Article

References (40)

1. Proteasome inhibitors: A novel class of potent and effective antitumor agents
2. Protease inhibitorinduced apoptosis: Accumulation of wt p53, p21WAF1/ClP1 and induction of apoptosis are independent markers of proteasome inhibition
3. Regulation of p53 stability
4. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
5. NCI's anticancer drug screening program may not be selecting for clinically active compounds
6. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
7. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition
8. Multiple myeloma
9. Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes
10. Regulation of transcription factors by protein degradation
11. p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts
12. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment
13. Inhibition of proteasome activities and subunit-specific amino-teminal threonine modification by lactacystin
14. The ubiquitin system
15. Ubiquitin-dependent protein degradation
16. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine
17. 2 in vitro and in vivo
18. Proteasome inhibitors: From research tools to drug candidates
19. p53-dependent induction of apoptosis by proteasome inhibitors
20. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
21. p53 status and the efficacy of cancer therapy in vivo
22. Cancer therapy and p53
23. Eponemycin exerts its antitumor effects through inhibition of proteasome function
24. The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets
25. Inactivation of wild type p53 tumor suppressor by electrophilic prostaglandins
26. The dual role of mutant p53 protein in chemosensitivity of human cancers
27. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway
28. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
29. Proteasomes are a target of the anti-tumour drug vinblastine
30. p53 expression, proliferative activity and prognosis in cancer
31. Structure-cytoprotective activity relationship of simple molecules containing an α,β-unsaturated carbonyl system
32. Prostaglandins in the treatment of cancer
33. Human ovarian cancer cell lines resistant to cisplatin, doxorubicin and L-phenylalanine mustard are sensitive to delta-7 prostaglandin A1 and delta-12 prostaglandin J2
34. Rational design of antitumor prostaglandins with high biological stability
35. Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity
36. Apoptosis induction resulting from proteasome inhibition
37. Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells
38. An information-intensive approach to the molecular pharmacology of cancer
39. Predicting response to chemotherapy: The role of p53
40. Nonhydrolyzable diubiquitin analogues are inhibitors of ubiquitin conjugation and deconjugation